icon-folder.gif   Conference Reports for NATAP  
 
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
 
 
 
Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-na´ve Patients Regardless of Race or Ethnicity
 
 
  Reported by Jules Levin
EASL 2011 March 30-April3 Berlin Germany
 
GM Dusheiko1*, MW Fried2, R Reddy3, DR Nelson4, N Bzowej5, N Adda6, CI Wright6, L Bengtsson6, S George6, SL Flamm7 1Royal Free and University College, London, UK, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of Pennsylvania School of Medicine, Philadelphia, PA, 4University of Florida, Gainesville, FL, 5California Pacific Medical Center, San Francisco, CA, 6Vertex Pharmaceuticals Incorporated, Cambridge, MA, 7Northwestern University, Chicago, IL, USA. *Address correspondence to: Professor Geoffrey M. Dusheiko, Centre for Hepatology, Royal Free Hospital & University College School Of Medicine Royal Free Hospital, London U.K.; Email: g.dusheiko@medsch.ucl.ac.uk

croi1.gif

croi2.gif

croi3.gif

croi4.gif

croi5.gif

croi6.gif

croi7.gif

croi8.gif

croi9.gif